Table 1.
Details of Included Study Populations
| Study | Country (Analysis Type) | Treatment Regimen | Follow-up, Years | No. Treated With FU (% With SVR) | Mean Age (SD)a | Male, % | Fibrosis Staging | Genotype |
|---|---|---|---|---|---|---|---|---|
| General cohorts | ||||||||
| Giannini 2001 [26] | Italy (prospective) | IFN-α | 3.0 | 36 (42) | 44 ± 11 | 78 | 7.3 ± 3.6b | GT1b 33%; non-GT1b 67% |
| Yoshida 2002 [27] | Japan (retrospective) | IFN-α or IFN-β | 5.4 | 2430 (34) | 50 ± 11 | 63 | 70% ≥F2; 9% F4 | NR |
| Imazeki 2003 [28] | Japan (retrospective) | IFN-α or IFN-β | 8.3 | 355 (33) | 49 ± 12 | 64 | 44% ≥F2; 13% F4 | GT1 74%; non-GT1 26% |
| Veldt 2004 [29] | Europe (retrospective) | IFN or IFN-α | 4.9 | 336 (85) | 42 (17–72) | 58 | 8% cirrhotic | GT1 40%; non-GT1 60% |
| Kasahara 2004 [30] | Japan (retrospective) | IFN monotherapy | 5.8 | 2698 (28) | 53 (20–76) | 64 | 71% ≥F2; 5% F4 | NR |
| Coverdale 2004 [19] | Australia (prospective) | IFN-α | 8.0 | 343 (15) | 37 (32–49) | 67 | 19% cirrhotic | GT1 38%; non-GT1 62% |
| Yu 2006 [31] | Taiwan (retrospective-prospective) | IFN-α ± RBV | 5.2 | 1057 (68) | 47 ± 12 | 60 | 16% cirrhotic | GT1 46%; non-GT1 54% |
| Arase 2007 [32] | Japan (retrospective) | IFN-α or IFN-β ± RBV | 7.5 | 500 (28) | 64 ± 3 | 50 | 52% ≥F2; 14% F4 | GT1b 60%; non-GT1b 40% |
| Backus 2011 [14] | United States Vets (retrospective) | Peg-IFN + RBV | 3.7 | 16 864 (44) | 52 ± 6 | 96 | 13% cirrhotic | GT1 72%; non-GT1 28% |
| Innes 2011 [33] | Scotland (retrospective) | IFN or Peg-IFN ± RBV | 5.3 | 1215 (46) | 42 ± 10 | 69 | 14% cirrhotic | GT1 36%; non-GT1 55% |
| Reimer 2011 [34] | Germany (retrospective) | Peg-IFN + RBV | 3.0 | 508 (56) | 50 ± 13 | 58 | NR | GT1 57%; non-GT1 43% |
| Di Martino 2011 [35] | France (prospective) | IFN or Peg-IFN ± RBV | 4.9 | 184 (32) | 42 ± 13 | 67 | 70% ≥F2; 11% cirrhotic | GT1 57%; non-GT1 43% |
| Maruoka 2012 [36] | Japan (retrospective) | IFN-α or IFN-β ± RBV | 10.4 | 577 (38) | 50 ± 12 | 64 | 47% ≥F2; 10% F4 | GT1 31%; GT2 69% |
| Cozen 2013 [37] | United States (retrospective) | IFN-α ± RBV | 10.0 | 140 (49) | 60 ± 7 | 99 | 59% ≥F2; 11% F4 | GT1 66%; non-GT1 34% |
| Rutter 2013 [38] | Austria (NR) | IFN or Peg-IFN ± RBV | 5.0 | 454 (73) | 50 ± 12 | 62 | 38% F3/F4 | GT1 66%; non-GT1 34% |
| Singal 2013 [39] | United States (retrospective) | Peg-IFN + RBV | 5.2 | 217 (38) | 48 (43–54) | 51 | 17% cirrhotic | GT1 69%; non-GT1 31% |
| Dieperink 2014 [13] | United States Vets (retrospective) | IFN, Peg-IFN or CIFN ± RBV | 7.5 | 536 (41) | 51 ± 6 | 98 | 82% ≥F2; 27% F4 | GT1 70%; non-GT1 30% |
| Overall (17 studies) | 5.2 (IQR 4.3–7.8)c | 28 451 (42) | 51 | 83 | 67% ≥F2; 12% F4 | GT1 66% | ||
| Cirrhotic cohorts | ||||||||
| Kumar 2005 [40] | India (prospective) | IFN-α ± RBV | 1.6 | 25 (32) | 52 ± 14 | 80 | 80% F4; 20% DC | GT1 31%; GT3 62% |
| Braks 2007 [41] | France (retrospective) | IFN-α or Peg-IFN ± RBV | 7.6 | 113 (33) | 54 ± 11 | 61 | 100% F4 | GT1 61%; non-GT1 39% |
| Bruno 2007 [42] | Italy (retrospective) | IFN monotherapy | 8.0 | 893 (14) | 55 ± 9 | 63 | 100% F4 | GT1 72%; non-GT1 28% |
| Mallet 2008 [43] | France (retrospective) | IFN-α or Peg-IFN ± RBV | 9.8 | 96 (41) | 45 (36–56) | 60 | 100% F4 | GT1 53%; non-GT1 47% |
| Morgan 2010 [20] | United States (prospective) | Peg-IFN + RBV | 6.8 | 526 (27) | 49 ± 8 | 72 | 100% ≥F3; 35% F4 (no DC) | GT1 87%; non-GT1 13% |
| Iacobellis 2011 [21] | Italy (prospective) | Peg-IFN + RBV | 4.2 | 75 (32) | 61 ± 9 | 63 | 100% DC | GT1 57%; non-GT1 43% |
| Van der Meer 2012 [44] | Europe and Canada (retrospective) | IFN, Peg-IFN or CIFN ± RBV | 8.4 | 530 (36) | 48 (42–56) | 70 | 100% ≥F3; 54% F4 (no DC) | GT1 68%; non-GT1 32% |
| Aleman 2013 [45] | Sweden (prospective) | Peg-IFN + RBV | 5.3 | 303 (36) | 51 ± 9 | 68 | 100% F4 | GT1 47%; non-GT1 53% |
| Kutala 2014 [46] | France (retrospective) | IFN-α or Peg-IFN ± RBV | 5.9 | 325 (32) | 49 (43–57) | 68 | 100% ≥F3; 51% F4 | GT1 55%; non-GT1 45% |
| Overall (9 studies) | 6.8 (IQR 5.8–7.9)c | 2,886 (27) | 51 | 67 | 100% ≥F3; 74% F4orDC | GT1 68% | ||
| HIV coinfected cohorts | ||||||||
| Limketkai 2012 [47] | United States (prospective) | IFN-α or Peg-IFN + RBV | 5.2 | 212 (17) | 46 (41–50) | 66 | 42% ≥F2 | GT1 91%; non-GT1 9% |
| Berenguer 2012 [12] | Spain (retrospective-prospective) | IFN-α or Peg-IFN + RBV | 5.0 | 1599 (39) | 40 (37–43) | 75 | 39% F3/F4 | GT1 49%; non-GT1 51% |
| P-Gonzalez 2013 [48] | Brazil (retrospective) | Peg-IFN + RBV | 2.0 | 42 (33) | 44 (29–67) | 78 | 48% F4 | GT1 54%; non-GT1 46% |
| Mira 2013 [49] | Spain (prospective) | Peg-IFN + RBV | 4.6 | 166 (26) | 43 (39–48) | 86 | 100% F4 | GT1 58%; non-GT1 42% |
| Labarga 2014 [50] | Spain (retrospective) | Peg-IFN + RBV | 6.1 | 339 (41) | 41 | 78 | 40% F3/F4 | GT1or4 73% |
| Overall (5 studies) | 5.0 (IQR 4.6–5.2)c | 2,358 (36) | 41 | 75 | 42% ≥F3 | GT1 57% | ||
Abbreviations: CIFN, consensus interferon; DC, decompensated cirrhosis; FU, follow-up; GT, genotype; HIV, human immunodeficiency virus; IFN, interferon; IQR, interquartile range; NR, not reported; Peg-IFN, pegylated interferon; RBV, ribavirin; SD, standard deviation; SVR, sustained virologic response.
a Median (IQR) reported when unavailable.
b Mean hepatitc activity index score (SD).
c Median of median follow-up times and IQR.